NCT03387865Recruiting
A Clinico-biological Database of Lung Cancers
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
This prospective, single-center, interventional study is conducted in order to achieve a biological bank accompanied by clinical data. Blood samples, optional tumor tissue and fecal samples are collected, processed and banked for all the included subjects. Those samples are collected before the start of treatment, at the time of first tumor assessment, at the time of first and second disease progression. The subjects are treated according to standard of care. Clinical data are collected at each sampling time. The primary objective of the study is to identify biological, clinical and tumoral factors associated with tumor response according SOC treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 21 Nov 2017
- Start date
- 13 Mar 2019
- Primary completion date
- Mar 2032
- Lead sponsor
- University Hospital, Lille
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT03387865
What you commit to
- Study type: Observational
- Planned participants: 500
- From 13 Mar 2019 to the primary completion date, Mar 2032
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with a history of treatment by antineoplastic chemotherapy, radio-chemotherapy, radiotherapy or targeted therapy, or presenting a contra indication to antineoplastic treatment administration
Other
- Subject is not willing to sign the informed consent form
- Subject is not registered with a social security scheme
- Subject is not francophone
- Subject is deprived of his/her liberty or under trusteeship
Who the study is looking for
- Documented new diagnosis of lung cancer by histology or cytology, or lung tumor leading to lung cancer suspicion without diagnosis for which an antineoplastic treatment is indicated
- Indication of a treatment by surgery, chemotherapy, radio-chemotherapy, radiotherapy or targeted therapy as first line of lung cancer treatment
- ability of the subject to follow study procedures
- Age \> 18 years
- Subject must have at least one measurable and/or assessable lesion in regard with RECIST 1.1 criteria
- Subject is registered with a social security scheme
- Subject is taken in charge at Pneumology department of Lille UH
- Subject has signed an informed consent form
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hôpital Calmette, CHU Coordinator of this site? Confirm its status | Lille | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.